Monopar Therapeutics Business Summary

Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company that operates primarily through a research and development-heavy business model, generating revenue through strategic licensing agreements, collaborations, and capital market transactions rather than commercial product sales. The company’s primary business segments are divided into targeted radiopharmaceuticals, which utilize its proprietary MNPR-101 antibody for imaging and treating advanced cancers, and rare disease therapeutics, headlined by ALXN1840 for Wilson disease. Monopar’s market strategy focuses on acquiring late-stage assets from larger pharmaceutical firms—such as its 2024 acquisition of ALXN1840 from AstraZeneca—to accelerate its path to New Drug Application (NDA) filings. Within the competitive landscape, Monopar contends with oncology and rare disease specialists such as Iovance Biotherapeutics, Oculis, and Upstream Bio, positioning itself as a high-volatility, small-cap innovator focused on high-unmet-need orphan indications. The company was co-founded in 2014 by a team of industry veterans including CEO Chandler Robinson, MD, Executive Chairman Christopher Starr, PhD, and EVP of R&D Andrew Mazar, PhD. Dr. Robinson previously co-founded Wilson Therapeutics (acquired by Alexion) and Tactic Pharma, while Dr. Starr brings a significant pedigree as the co-founder of BioMarin Pharmaceutical and Raptor Pharmaceuticals (acquired by Horizon). The current leadership team is further bolstered by Chief Financial Officer Quan Vu, who joined in late 2024 with a background in investment banking and corporate strategy, and Chief Operating Officer Andrew Cittadine. Notable governance and investment support include board member Lavina Talukdar, currently the Head of Investor Relations at Moderna, and institutional backing from Hendricks Holding Company, reflecting a leadership core with deep experience in orphan drug commercialization and successful biotech exits.